Marcia Brose

  • Dr. Brose is an Associate Professor at the University Of Pennsylvania School Of Medicine, in Otorhinolaryngology: Head and Neck Surgery, and Medicine, Hematology/Oncology. She is the Director of the Thyroid Cancer Therapeutics Program and Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center. She is an internationally recognized leader in the field of thyroid cancer oncology, lecturing in the US, Europe, Asia and South America. She is the global co-PI of DECISION, which lead to the first FDA approval in this indication as well as ongoing trials RIFTOS and VERIFY. She is the global PI of the international multicenter phase II study of Vemurafenib in patients with RAI refractory papillary thyroid cancer recently published in Lancet Oncology. She is a Co-Investigator of the pivotal phase III trials EXAM (cabozantinib in medullary thyroid cancer) and SELECT (lenvatinib in differentiated thyroid cancer) both of which lead to FDA approvals.


     

 

Leave a Reply